Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients
Eduardo Aparicio-Minguijón; Jorge Boán; Antonio Terrón; Carlos Heredia; Cristina Puente; Asunción Pérez-Jacoiste Asín; M. Ángeles Orellana; Laura Domínguez; José Manuel Caro; M. Jesús López-Gude; Eva María Aguilar-Blanco; Andrea Eixerés-Esteve; Francisco López-Medrano;
Enferm Infecc Microbiol Clin. 2025;43:86-92
Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years
Alejandro Salinas-Botrán; Carmen Olmos-Blanco; David Fernández de Velasco-Pérez; Alicia Guzmán-Carreras; Alejandro Morales-Rosas; Daniel Gómez-Ramírez;
Enferm Infecc Microbiol Clin. 2025;43:71-9
Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing?
Marta Díaz-Navarro; Rama Hafian; María Jesús Pérez-Granda; Emilia Cercenado; Patricia Muñoz; María Guembe;
Enferm Infecc Microbiol Clin. 2024;42:435-8